Genetic modulation of tumor antigen presentation.

Abstract

An effective cancer-cell vaccine is created by expressing major-histocompatibility-complex (MHC) class II molecules without the invariant chain protein (Ii) that normally blocks the antigenic-peptide-binding site of MHC class II molecules at their synthesis in the endoplasmic reticulum. Such tumor-cell constructs are created either by the transfer of genes for MHC class IIalpha and beta chains, or by the induction of MHC class II molecules and Ii protein with a transacting factor, followed by Ii suppression using antisense methods. Preclinical validation of this approach is reviewed with the goal of using this immunotherapy for metastatic human cancers.

• Authors: M Xu, G Qiu, Z Jiang, E von Hofe, R E Humphreys
• Journal: Trends in biotechnology (Trends Biotechnol) Vol. 18 Issue 4 Pg. 167-72 (Apr 2000) ISSN: 0167-7799 [Print] England
• PMID: 10740263 (Publication Type: Journal Article, Review)

Chemical References

• Antigens, Differentiation, B-Lymphocyte
• Antigens, Neoplasm
• Cancer Vaccines
• Histocompatibility Antigens Class II
• Vaccines, Synthetic
• invariant chain

Topics

• Animals
• Antigens, Differentiation, B-Lymphocyte (genetics, metabolism)
• Antigens, Neoplasm (genetics)
• CD4-Positive T-Lymphocytes (immunology, metabolism)
• Cancer Vaccines (genetics)
• Endoplasmic Reticulum (genetics, metabolism)
• Histocompatibility Antigens Class II (genetics, metabolism)
• Humans
• Immunotherapy (methods)
• Neoplasm Metastasis (therapy)
• Vaccines, Synthetic (genetics)